Niramai AI: How an Indian Startup Is Transforming Breast Cancer Screening

Niramai stands for Non-Invasive Risk Assessment with Machine Intelligence. Founded in 2016 by Dr. Geetha Manjunath (former researcher at Xerox Research and HP Labs) and Nidhi Mathur, the startup aims to make breast screening accessible, affordable, and stress-free for women worldwide.

Instead of ionizing X-rays, Niramai analyzes infrared metabolic heat signatures and abnormal blood vessel configurations to generate an objective risk score for clinicians.

How Niramai Ai Works?

Niramai uses Artificial Intelligence (AI), Machine Learning (ML), and Infrared Thermal Imaging to analyse temperature patterns around the breast. Its technology, called Thermalytix, helps doctors identify suspicious thermal patterns that may indicate an abnormality and decide whether further medical tests are needed.

Niramai's approach is different from traditional breast screening because it does not use ionising X-ray radiation and does not require physical contact during the thermal scan.

1. Infrared Thermal Scanning

A specialised infrared thermal camera captures temperature patterns from the breast area without touching the body. The process is non-invasive and radiation-free.

2. Thermal Image Processing

The captured images are converted into digital thermal maps. These maps show differences in temperature across different areas of the breast.

3. AI and Machine Learning Analysis

Niramai's AI algorithms analyse temperature variations, asymmetrical heat patterns and vascular patterns to identify suspicious thermal characteristics.

4. Automated Risk Assessment Report

The system generates a report that helps healthcare professionals assess potential abnormalities and understand whether additional tests are required.

5. Doctor's Evaluation

A doctor reviews the report and may recommend further investigations such as mammography, ultrasound or biopsy, depending on the patient's condition.

1. Thermalytix (Core AI Software Solution)

The flagship AI platform for point-of-care breast screening and risk stratification.

• 400,000+ Thermal Points: Evaluates high-resolution heat distribution across breast tissue without physical touch.

• Machine Learning Detection: Identifies abnormal vascular growth and metabolic heat patterns typical of early-stage tumors.

• Radiation-Free & Painless: Eliminates X-rays and tissue compression, maintaining 100% patient privacy.

• Automated Clinical Reports: Generates an objective breast health score to help physicians decide on follow-up investigations.

2. SMILE-100 (Thermal Imaging Medical Device)

A specialized, certified hardware medical device designed for recording breast surface temperatures in clinical environments.

• US FDA 510(k) Cleared: Approved as a regulated adjunctive thermal imaging tool for breast evaluation.

• Clinical Accuracy: Captures stable, high-fidelity infrared images directly into the Thermalytix platform.

• Contact-Free Operation: Non-contact hardware setup ensures maximum patient comfort.

3. Mythri (Portable Screening Solution)

A lightweight, mobile-first screening setup designed to bring Thermalytix to primary care.

• Rural & Outreach Focus: Optimized for primary health centers (PHCs), mobile medical vans, and corporate health camps.

• Scalable & Cost-Effective: Drastically lowers screening costs and equipment footprints in remote areas.

4. Thermalytix Edge AI (On-Premise Processing)

An edge-computing deployment that removes reliance on continuous high-speed cloud connectivity.

• Local Processing: Runs AI models on dedicated on-site hardware within hospitals or diagnostic labs.

• Data Privacy & Speed: Ensures rapid report generation and on-premise patient data security.

No, Niramai AI cannot independently confirm whether a woman has breast cancer or not.

Niramai's Thermalytix Technology is primarily designed for breast screening and risk assessment. It uses Infrared Thermal Imaging and Artificial Intelligence to analyse temperature patterns and identify suspicious abnormalities.

If the screening report shows any suspicious signs, doctors may recommend additional medical tests to confirm the condition.

Which Additional Tests May Be Required?

• Early Detection in Younger Women:

  Lifestyle changes have led to an increase in breast health issues among women under 40. Younger women naturally have denser breast tissue, which often obscures tumors on standard X-ray mammograms. Niramai’s heat-based thermal AI works independently of tissue density, enabling reliable early screening for younger demographics.

• Zero Radiation and Pain:

  Standard mammograms carry cumulative radiation risks and require intense breast compression. Niramai is 100% radiation-free and completely painless, encouraging future generations to participate in regular preventive health screenings without physical trauma or hesitation.

• Total Privacy ("No-Touch, No-See"):

  Cultural hesitation, body shame, and modesty concerns frequently cause women to avoid clinical breast exams. Because the thermal sensors capture data from a distance without physical contact or visual exposure, screening rates are likely to increase substantially among younger, privacy-conscious individuals.

• Affordable and Widespread Access:

  Unlike massive, multi-million-rupee mammography suites, this setup is lightweight, portable, and low-cost. It can be easily integrated into local primary health centers (PHCs), mobile medical vans, and corporate wellness drives, bridging the urban-rural healthcare divide.

• False Sense of Security:

  A "Low Risk" or normal AI score might lead patients to ignore noticeable physical symptoms like lumps, nipple discharge, or persistent localized pain. Relying solely on AI without clinical breast awareness remains a significant risk.

• Susceptibility to Thermal Variations (False Alarms):

  Skin temperature is dynamic—it can be influenced by ambient weather, fever, physical exertion, menstrual cycles, or superficial skin infections. These external factors can trigger false-positive alerts, causing unnecessary emotional stress and leading to costly confirmatory procedures.

• Not a Standalone Diagnostic Tool:

  Niramai cannot conclusively diagnose or stage cancer. Any abnormal finding still mandates standard clinical pathways, including ultrasound, diagnostic mammograms, and tissue biopsies.

• Data Governance and Health Privacy:

  With high-volume digital health tracking, safeguarding sensitive medical data, thermal imaging sets, and diagnostic histories against data breaches will remain a growing challenge for future healthcare networks.

Official Website:https://niramai.com